Comparing treatment options for large vessel vasculitis

References

• Jennette JC, Falk RJ, Bacon PA, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65:1–11.
   Google Scholar
• Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Takayasu arteritis and giant cell arteritis. Medicine (Baltimore). 2009;88:221–226.
   PubMed Web of Science ®Google Scholar
• Dejaco C, Duftner C, Buttgereit F, et al. The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Rheumatology. 2016; kew273.
   Google Scholar
• Koster MJ, Matteson EL, Warrington KJ. Large-vessel giant cell arteritis: diagnosis, monitoring and management. Rheumatology. 2018;57:ii32–ii42.
   PubMedGoogle Scholar
• Maz M, Chung SA, and Abril A, et al. American college of rheumatology/vasculitis foundation guideline for the management of giant cell arteritis and takayasu arteritis. Arthritis Care Res (Hoboken). 2021;73:1071–1087.
   PubMed Web of Science ®Google Scholar
• Hellmich B, Agueda A, and Monti S, et al. Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2018 2020;79:19–30.
   Google Scholar
• Mackie SL, Dejaco C, and Appenzeller S, et al. British society for rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. Rheumatology. 2020;59:487–494.
   PubMedGoogle Scholar
• Dejaco C, Ramiro S, Duftner C, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis. 2018.
   Google Scholar
• Chevalet P, Barrier JH, Pottier P, et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol. 2000;27:1484–1491.
   PubMed Web of Science ®Google Scholar
• Hellmich B, Buttgereit F. GCA management guidelines — vive la différence? Nat Rev Rheumatol. 2021.
   PubMedGoogle Scholar
• Singh AG, Kermani TA, and Crowson CS, et al. Visual manifestations in giant cell arteritis: trend over five decades in a Population-based Cohort. J Rheumatol. 2015;42:309–315.
   PubMed Web of Science ®Google Scholar
• Hayreh SS, Zimmerman B. Management of giant cell arteritis: our 27-year clinical study: new light on old controversies. Ophthalmologica. 2003.
   Google Scholar
• Mazlumzadeh M, Hunder GG, Easley KA, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum. 2006;54:3310–3318.
   PubMed Web of Science ®Google Scholar
• Hayreh SS, Zimmerman B, Kardon RH. Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta Ophthalmol Scand. 2002.
   PubMedGoogle Scholar
• Hayreh SS, Zimmerman B. Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology. 2003.
   Google Scholar
• Salvarani C, Della Bella C, Cimino L, et al. Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. Rheumatology. 2009.
   Google Scholar
• Berger CT, Wolbers M, Meyer P, et al. High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition. Rheumatology. 2009.
   PubMedGoogle Scholar
• Hayreh SS, Podhajsky PA, and Zimmerman B. Ocular manifestations of giant cell arteritis. Am J Ophthalmol. 1998;125:509–520.
   PubMed Web of Science ®Google Scholar
• Soriano A, Muratore F, Pipitone N, et al. Visual loss and other cranial ischaemic complications in giant cell arteritis. Nat Rev Rheumatol. 2017;13:476–484.
   PubMed Web of Science ®Google Scholar
• Stone J, Tuckwell K, and Dimonaco S, et al. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med. 2017;377: 317–328.
   PubMed Web of Science ®Google Scholar
• JA J, C H-G, IC M, et al. Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134:106–114.
   PubMedGoogle Scholar
• Hoffman GS, Cid MC, Hellmann DB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 2002;46:1309–1318.
   PubMed Web of Science ®Google Scholar
• Spiera RF, Mitnick HJ, and Kupersmith M, et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol. 2001;19:495–501.
   PubMed Web of Science ®Google Scholar
• Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis an individual patient data meta-analysis. ARTHRITIS Rheum. 2007;56:2789–2797.
   PubMed Web of Science ®Google Scholar
• Koster MJ, Yeruva K, Crowson CS, et al. Efficacy of methotrexate in real-world management of giant cell arteritis: a case-control study. J Rheumatol. 2019;46:501–508.
   PubMed Web of Science ®Google Scholar
• Mackie SL, Dejaco C, Appenzeller S, et al. British society for rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatology. 2020;59:e1–e23.
   PubMed Web of Science ®Google Scholar
• Bienvenu B, Ly KH, Lambert M, et al. Management of giant cell arteritis: recommendations of the french study group for large vessel vasculitis (GEFA). La Revue de Médecine Interne. 2016;37(3):154–165.
   PubMedGoogle Scholar
• A T, C D, D C, et al. Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series. Int J Clin Pract. 2012;66(9):906–909.
   PubMedGoogle Scholar
• Diamantopoulos AP, Hetland H, Myklebust G. Clinical study leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series. Biomed Res Int. 2013;2013:1–3.
   Web of Science ®Google Scholar
• Hočevar A, Ješe R, Rotar Ž, et al. Does leflunomide have a role in giant cell arteritis? An open-label study. Clinical Rheumatology. 2019;38(2):291–296.
   PubMed Web of Science ®Google Scholar
• De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis. 1986;45(2):136–138.
   PubMed Web of Science ®Google Scholar
• de Boysson H, Boutemy J, Creveuil C, et al. Is there a place for cyclophosphamide in the treatment of giant-cell arteritis? A case series and systematic review. Semin Arthritis Rheum. 2013;43(1):105–112.
   PubMed Web of Science ®Google Scholar
• Büttner T, Heye N, Przuntek H. Temporal arteritis with cerebral complications: report of four cases. Eur Neurol. 1994;34(3):162–167.
   PubMedGoogle Scholar
• Hoffman GS, Leavitt Y, and Kerr GS, et al. Treatment of glucocorticoid-resistant or relapsing takayasu arteritis with methotrexate. Arthritis & Rheumatism. 1994;37(4):578–582.
   PubMed Web of Science ®Google Scholar
• Shinjo SK, Pereira RMR, Tizziani VAP, et al. Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis. Clinical Rheumatology. 2007;26(11):1871–1875.
   PubMed Web of Science ®Google Scholar
• Valsakumar AK, Valappil UC, Jorapur V, et al. Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu’s arteritis. J Rheumatol. 2003;30(8):1793–1798.
   PubMed Web of Science ®Google Scholar
• Shelhamer JH, Volkman, DJ, and Parrillo, JE, et al. Takayasu’s arteritis and its therapy. Ann Intern Med. 1985;103(1):121–126.
   PubMed Web of Science ®Google Scholar
• S Y, M L, M L, et al. Cyclophosphamide could be a better choice than methotrexate as induction treatment for patients with more severe Takayasu’s arteritis. Rheumatol Int. 2017;37(12):2019–2026.
   PubMedGoogle Scholar
• Villiger PM, Adler S, Kuchen S, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387(10031):1921–1927.
   PubMed Web of Science ®Google Scholar
• Castañeda S, Prieto-Peña D, and Vicente-Rabaneda EF, et al. Advances in the Treatment of Giant Cell Arteritis. J Clin Med. 2022;11(4):1588.
   PubMedGoogle Scholar
• Adler S, Reichenbach S, Gloor A, et al. Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis. Rheumatology. 2019;58(9):1639–1643.
   PubMedGoogle Scholar
• Stone JH, Spotswood H, Unizony SH, et al. New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension. Rheumatology. 2021.
   Google Scholar
• Stone JH, Han J, and Aringer M, et al. Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the giant cell arteritis actemra (GiACTA) trial. Lancet Rheumatol. 2021;3(5):e328–e336.
   Google Scholar
• Christ L, Seitz L, and Scholz G, et al. Tocilizumab monotherapy after ultra-short glucocorticoid administration in giant cell arteritis: a single-arm, open-label, proof-of-concept study. Lancet Rheumatol. 2021;3(9):e619–e626.
   Google Scholar
• Prieto-Pena D, Calderón-Goercke M, and Loricera J, et al. Real-world comparative study of methotrexate vs tocilizumab in patients with giant cell arteritis with large vessel involvement [abstract]. Arthritis Rheumatol. 2019:71.
   Google Scholar
• Calderón-Goercke M, Castañeda S, Aldasoro V, et al. Tocilizumab in refractory giant cell arteritis. monotherapy versus combined therapy with conventional immunosuppressive drugs. observational multicenter study of 134 patients. Semin Arthritis Rheum. 2021;51(2):387–394.
   PubMed Web of Science ®Google Scholar
• Schönau V, Roth J, Tascilar K, et al. Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the Riga study. Rheumatology (Oxford). 2021;60(8):3851–3861.
   PubMedGoogle Scholar
• Prieto-González S, Terrades-García N, Corbera-Bellalta M, et al. Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients. RMD Open. 2017;3(2):e000570.
   PubMedGoogle Scholar
• Baldini M, Maugeri N, Ramirez GA, et al. Selective up-regulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: relevance for recent optic nerve ischemia. Arthritis Rheum. 2012;64(3):854–865.
   PubMedGoogle Scholar
• Ramirez GA, Rovere-Querini P, and Blasi M, et al. PTX3 Intercepts Vascular Inflammation in Systemic Immune-Mediated Diseases. Front Immunol. 2019;10:10.
   PubMedGoogle Scholar
• Gloor AD, Yerly D, Adler S, et al. Immuno-monitoring reveals an extended subclinical disease activity in tocilizumab-treated giant cell arteritis. Rheumatology. 2018;57(10):1795–1801.
   PubMedGoogle Scholar
• Kaneko Y, Takeuchi T. An update on the pathogenic role of IL-6 in rheumatic diseases. Cytokine. 2021;146:155645.
   PubMedGoogle Scholar
• Saruhan-Direskeneli G, Bıçakçıgil M, Yılmaz V, et al. Interleukin (IL)–12, IL-2, and IL-6 Gene Polymorphisms in Takayasu’s Arteritis from Turkey. Hum Immunol. 2006;67(9):735–740
   PubMedGoogle Scholar
• Nakaoka Y, Isobe M, and Takei S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis. 2018;77(3):348–354.
   PubMed Web of Science ®Google Scholar
• Nakaoka Y, Isobe M, Tanaka Y, et al. Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study. Rheumatology. 2020;59(9):2427–2434.
   PubMed Web of Science ®Google Scholar
• Mekinian A, Biard L, and Dagna L, et al. Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: multicenter retrospective study of 209 patients. Rheumatology (Oxford). 2022;61:1376–1384.
   PubMedGoogle Scholar
• Hoffman GS, Cid C, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med. 2007;146(9):621–630.
   PubMed Web of Science ®Google Scholar
• Seror R, Baron G, Hachulla E, et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Ann Rheum Dis. 2014;73(12):2074–2081
   PubMed Web of Science ®Google Scholar
• Martínez-Taboada VM, Rodríguez-Valverde V, Carreño L, et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Annals of the Rheumatic Diseases. 2007;67(5):625–630.
   PubMed Web of Science ®Google Scholar
• Cantini F, Niccoli L, Salvarani C, et al. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum. 2001;44(12):2933–2935.
   PubMed Web of Science ®Google Scholar
• Molloy ES, Langford CA, Clark TM, et al. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis. 2008;67(11):1567–1569.
   PubMed Web of Science ®Google Scholar
• S J, K TA, B AK, et al. Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term followup. Arthritis Care Res (Hoboken). 2012;64(7):1079–1083.
   PubMedGoogle Scholar
• M A, C C, Resche-Rigon M, et al. Efficacy of biological-targeted treatments in takayasu arteritis: multicenter, retrospective study of 49 patients. Circulation. 2015;132(18):1693–1700.
   PubMedGoogle Scholar
• Maz M, Chung SA, and Abril A, et al. American college of rheumatology/vasculitis foundation guideline for the management of giant cell arteritis and takayasu arteritis. arthritis rheumatol. Vol. 73, (Hoboken NJ); 2021. 1349–1365.
   Google Scholar
• C C, T A, G E, et al. Failure of first anti-TNF agent in Takayasu’sarteritis: to switch or to swap? Clin Exp Rheumatol. 2021;39(2):S129–S134.
   Google Scholar
• Ciccia F, Rizzo A, Ferrante A, et al. New insights into the pathogenesis of giant cell arteritis. Autoimmun Rev. 2017;16(7):675–683.
   PubMed Web of Science ®Google Scholar
• Ciccia F, Macaluso F, Mauro D, et al. New insights into the pathogenesis of giant cell arteritis: are they relevant for precision medicine? Lancet Rheumatol. 2021;3(12):e874–e885.
   Google Scholar
• Langford CA, Cuthbertson D, and Ytterberg SR, et al. A randomized, double-blind trial of abatacept (ctla-4ig) for the treatment of giant cell arteritis. Arthritis Rheumatol. 2017;69(4):837–845.
   PubMed Web of Science ®Google Scholar
• Langford CA, Cuthbertson D, Ytterberg SR, et al. A randomized, double-blind trial of abatacept (ctla-4ig) for the treatment of takayasu arteritis. Arthritis Rheumatol. 2017;69(4):846–853.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Chen Z, Hu L, et al. Calreticulin blockade attenuates murine acute lung injury by inducing polarization of m2 subtype macrophages. Front Immunol. 2020;11:11.
   PubMed Web of Science ®Google Scholar
• Conway R, O’Neill L, Gallagher P, et al. Ustekinumab for refractory giant cell arteritis: a prospective 52-week trial. Semin Arthritis Rheum. 2018;48(3):523–528.
   PubMed Web of Science ®Google Scholar
• Matza MA, Fernandes AD, and Stone JH, et al. Ustekinumab for the treatment of giant cell arteritis. Arthritis Care Res (Hoboken). 2021;73:893–897.
   PubMedGoogle Scholar
• Espígol-Frigolé G, Planas-Rigol E, Lozano E, et al. Expression and function of IL12/23 related cytokine subunits (p35, p40, and p19) in giant-cell arteritis lesions: contribution of p40 to th1- and th17-mediated inflammatory pathways. Front Immunol. 2018;9.
   PubMedGoogle Scholar
• Venhoff N, Schmidt WA, Lamprecht P, et al. Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial. Trials. 2021;22(1):543.
   PubMedGoogle Scholar
• Terao C, Yoshifuji H, Kimura A, et al. Two susceptibility loci to takayasu arteritis reveal a synergistic role of the il12b and hla-b regions in a japanese population. Am J Hum Genet. 2013;93:289–297.
   PubMed Web of Science ®Google Scholar
• Saur S-J, Horger M, and Henes J. Successful treatment with the IL12/IL23 antagonist ustekinumab in a patient with refractory Takayasu arteritis. Rheumatol Adv Pract. 2021;5:rkaa082.
   PubMedGoogle Scholar
• Gon Y, Yoshifuji H, Nakajima T, et al. Long-term outcomes of refractory Takayasu arteritis patients treated with biologics including ustekinumab. Mod Rheumatol. 2021;31:678–683.
   PubMedGoogle Scholar
• Schmits R, Kubuschok B, Schuster S, et al. Analysis of the B cell repertoire against autoantigens in patients with giant cell arteritis and polymyalgia rheumatica. Clin Exp Immunol. 2002;127:379–385.
   PubMedGoogle Scholar
• Graver JC, Boots AMH, and Haacke EA, et al. Massive b-cell infiltration and organization into artery tertiary lymphoid organs in the aorta of large vessel giant cell arteritis. Front Immunol. 2019;10:83.
   PubMedGoogle Scholar
• Ciccia F, Rizzo A, Maugeri R, et al. Ectopic expression of CXCL13, BAFF, April and LT-β is associated with artery tertiary lymphoid organs in giant cell arteritis. Ann Rheum Dis. 2017;76:235–243.
   PubMedGoogle Scholar
• Shibata A, Kondo T, and Kurasawa T, et al. A case of polyangiitis overlap syndrome of giant cell arteritis and granulomatosis with polyangiitis successfully treated with rituximab. Mod Rheumatol Case Reports 2020;5:317–321.
   Google Scholar
• Mulhearn B, Cooper E, and Knights S. Rituximab fails to treat giant cell arteritis in a patient with ACPA-positive rheumatoid arthritis. Rheumatol Adv Pract. 2021;5:rkab020.
   PubMedGoogle Scholar
• Bhatia A. Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis. 2005;64:1099–1100.
   PubMed Web of Science ®Google Scholar
• Mayrbaeurl B, Hinterreiter M, Burgstaller S, et al. The first case of a patient with neutropenia and giant-cell arteritis treated with rituximab. Clin Rheumatol. 2007;26:1597–1598.
   PubMed Web of Science ®Google Scholar
• Kurata A, Saito A, Hashimoto H, et al. Difference in immunohistochemical characteristics between Takayasu arteritis and giant cell arteritis: it may be better to distinguish them in the same age. Mod Rheumatol. 2019;29:992–1001.
   PubMed Web of Science ®Google Scholar
• Mutoh T, Shirai T, Ishii T, et al. Identification of two major autoantigens negatively regulating endothelial activation in Takayasu arteritis. Nat Commun. 2020;11:1253.
   PubMed Web of Science ®Google Scholar
• Galarza C, Valencia D, Tobón GJ, et al. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases? Clin Rev Allergy Immunol. 2008;34:124–128.
   PubMed Web of Science ®Google Scholar
• Ernst D, Greer M, Stoll M, et al. Remission achieved in refractory advanced takayasu arteritis using rituximab. Case Rep Rheumatol. 2012;2012:1–4.
   Google Scholar
• Caltran E, Di Colo G, and Ghigliotti G, et al. Two Takayasu arteritis patients successfully treated with rituximab. Clin Rheumatol. 2014;33:1183–1184.
   PubMed Web of Science ®Google Scholar
• Walters HM, Aguiar CL, MacDermott EJ, et al. Takayasu arteritis presenting in the context of active tuberculosis. J Clin Rheumatol. 2013;19:344–347.
   PubMedGoogle Scholar
• Pazzola G, Muratore F, Pipitone N, et al. Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature. Rheumatology. 2018;57:1151–1155.
   PubMed Web of Science ®Google Scholar
• Nakagomi D, Kronbichler A, Witte T, et al. Comment on: rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature. Rheumatology. 2018;57:1309–1310.
   PubMedGoogle Scholar
• Zhang H, Watanabe R, Berry GJ, et al. Inhibition of JAK-STAT signaling suppresses pathogenic immune responses in medium and large vessel vasculitis. Circulation. 2018;137:1934–1948.
   PubMed Web of Science ®Google Scholar
• Koster M, Crowson C, and Giblon R, et al. Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study. Ann Rheum Dis. 2022;81:861–867.
   PubMed Web of Science ®Google Scholar
• Sato S, Matsumoto H, Temmoku J, et al. A case of Takayasu arteritis complicated by refractory ulcerative colitis successfully treated with tofacitinib. Rheumatology. 2020;59:1773–1775.
   PubMed Web of Science ®Google Scholar
• Kuwabara S, Tanimura S, Matsumoto S, et al. Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis. Ann Rheum Dis. 2020;79:1125–1126.
   PubMed Web of Science ®Google Scholar
• Palermo A, Marvisi C, and Casali M, et al. Tofacitinib for the treatment of refractory Takayasu’s arteritis: description of 2 cases. Clin Exp Rheumatol. 2020;38(1):234–235.
   PubMedGoogle Scholar
• Narváez J, Bernad B, and Gómez-Vaquero C, et al. Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis. Clin Exp Rheumatol. 2008;26:S57–62.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Casali B, and Farnetti E, et al. P1A1/A2 polymorphism of the platelet glycoprotein receptor IIIa and risk of cranial ischemic complications in giant cell arteritis. Arthritis Rheum. 2007;56:3502–3508.
   PubMedGoogle Scholar
• Pugnet G, Sailler L, Fournier J-P, et al. Predictors of cardiovascular hospitalization in giant cell arteritis: effect of statin exposure. a french population-based study. J Rheumatol. 2016;43:2162–2170.
   PubMedGoogle Scholar
• de Souza Aws, Machado NP, Pereira VM, et al. Antiplatelet therapy for the prevention of arterial ischemic events in takayasu arteritis. Circ J. 2010;74:1236–1241.
   PubMedGoogle Scholar
• Seyahi E, Ugurlu S, Cumali R, et al. Atherosclerosis in Takayasu arteritis. Ann Rheum Dis. 2006;65:1202–1207.
   PubMed Web of Science ®Google Scholar
• Numano F, Kishi Y, TANAKA A, et al. Inflammation and atherosclerosis: atherosclerotic lesions in takayasu arteritis. Ann N Y Acad Sci. 2006;902:65–76.
   Google Scholar
• Filer A, Nicholls D, Corston R, et al. Takayasu arteritis and atherosclerosis: illustrating the consequences of endothelial damage. J Rheumatol. 2001;28:2752–2753.
   PubMedGoogle Scholar
• Rose AG, Sinclair-Smith CC. Takayasu’s arteritis. A study of 16 autopsy cases. Arch Pathol Lab Med. 1980;104:231–237.
   PubMedGoogle Scholar
• Espinola-Zavaleta N, Soto-López ME, Carreón-Torres E, et al. Altered flow-mediated vasodilatation, low paraoxonase-1 activity, and abnormal high-density lipoprotein subclass distribution in takayasu’s arteritis. Circ J. 2009;73:760–766.
   PubMedGoogle Scholar
• Cid MC, Unizony S, Pupim L, et al. OP0059 MAVRILIMUMAB (ANTI GM-CSF RECEPTOR Α MONOCLONAL ANTIBODY) REDUCES RISK OF FLARE AND INCREASES SUSTAINED REMISSION IN A PHASE 2 TRIAL OF PATIENTS WITH GIANT CELL ARTERITIS. Ann Rheum Dis. 2021;80:31.1–32.
   Google Scholar
• Jayne DRW, Merkel PA, Schall TJ, et al. Avacopan for the treatment of ANCA-Associated vasculitis. N Engl J Med. 2021;384:599–609.
   PubMed Web of Science ®Google Scholar